Melanoma whole-exome sequencing identifies (V600E)B-RAF amplification-mediated acquired B-RAF inhibitor resistance - Wikidata - wikimedia - TriplyDB

Melanoma whole-exome sequencing identifies (V600E)B-RAF amplification-mediated acquired B-RAF inhibitor resistance

Melanoma whole-exome sequencing identifies (V600E)B-RAF amplification-mediated acquired B-RAF inhibitor resistance

http://www.wikidata.org/entity/Q36489360

about

Tunable-combinatorial mechanisms of acquired resistance limit the efficacy of BRAF/MEK cotargeting but result in melanoma drug addiction.Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations Resistant mechanisms to BRAF inhibitors in melanoma The Complexity of the ERK/MAP-Kinase Pathway and the Treatment of Melanoma Skin Cancer Different Facets of Copy Number Changes: Permanent, Transient, and Adaptive MEK inhibitors and their potential in the treatment of advanced melanoma: the advantages of combination therapy Melanoma: oncogenic drivers and the immune system Cracking the Code of Human Diseases Using Next-Generation Sequencing: Applications, Challenges, and Perspectives The utility of transposon mutagenesis for cancer studies in the era of genome editing.Therapy for BRAFi-Resistant Melanomas: Is WNT5A the Answer?Combination Therapies to Inhibit the RAF/MEK/ERK Pathway in Melanoma: We are not Done Yet Ipilimumab, vemurafenib, dabrafenib, and trametinib: synergistic competitors in the clinical management of BRAF mutant malignant melanoma Universes collide: combining immunotherapy with targeted therapy for cancer New developments in dermatological oncogenetics Pathways and therapeutic targets in melanoma Tumour heterogeneity and the evolution of polyclonal drug resistance Targeted therapies in development for non-small cell lung cancer Melanoma: from mutations to medicine Targeting RAF kinases for cancer therapy: BRAF-mutated melanoma and beyond Raf-interactome in tuning the complexity and diversity of Raf function.Elucidating distinct roles for NF1 in melanomagenesis Imatinib for melanomas harboring mutationally activated or amplified KIT arising on mucosal, acral, and chronically sun-damaged skin Impact of MET expression on outcome in BRAF(V600E/K) advanced melanoma.Vemurafenib synergizes with nutlin-3 to deplete survivin and suppresses melanoma viability and tumor growth.A novel AKT1 mutant amplifies an adaptive melanoma response to BRAF inhibition Effects of AKT inhibitor therapy in response and resistance to BRAF inhibition in melanoma.Copy Number Changes Are Associated with Response to Treatment with Carboplatin, Paclitaxel, and Sorafenib in Melanoma Non-genomic and Immune Evolution of Melanoma Acquiring MAPKi Resistance Negative feedback regulation of the ERK1/2 MAPK pathway Modelling vemurafenib resistance in melanoma reveals a strategy to forestall drug resistance Functional profiling of live melanoma samples using a novel automated platform Genetic aberrations in imatinib-resistant dermatofibrosarcoma protuberans revealed by whole genome sequencing Clonal architectures and driver mutations in metastatic melanomas AEBP1 upregulation confers acquired resistance to BRAF (V600E) inhibition in melanoma A novel compound which sensitizes BRAF wild-type melanoma cells to vemurafenib in a TRIM16-dependent manner MERTK receptor tyrosine kinase is a therapeutic target in melanoma.Strategies for modern biomarker and drug development in oncology.Significance of the BRAF mRNA Expression Level in Papillary Thyroid Carcinoma: An Analysis of The Cancer Genome Atlas Data.Genomic dissection of Hurthle cell carcinoma reveals a unique class of thyroid malignancy Design and Development of Fluorescent Vemurafenib Analogs for In Vivo Imaging

P2860

Q24315032-FF565524-269B-47B5-B5F6-B2C6B01FA27B Q24632064-FEFBA1CE-29E3-4704-9CDE-1FA5A694A51E Q26739717-08223BB3-CBBC-437E-991F-0D92FE8C35F8 Q26747247-E673CD09-20DE-4F5E-9EAD-93EDCC930793 Q26769649-E33E40B5-4F12-4965-B922-C95F65DD02C3 Q26771192-BE8F7CE3-EC43-49B4-B9E4-B91EB133EF22 Q26775598-D1E56E77-797E-431B-85DE-4FE24CA5DB94 Q26776038-A4425B86-FFFC-4E56-B4A5-F6DF3DE1A99E Q26781762-0721EF88-2E1D-47F7-AA04-C7A94470B443 Q26782222-7069B721-2AD4-41A4-B163-4CB86E8D5A6A Q26799864-ECAD76A1-E96F-40B0-A3D6-F949BB027E8D Q26824310-97E886C8-8369-4C09-AD24-A4E61E6BD990 Q26825316-1950C9FB-5E83-44A4-9720-5EAB4163702D Q26853582-C42C5AE4-4917-45EE-8666-F3D489EEFBBB Q26865736-D58140DF-F850-4E54-98BD-A5DF3BFA3FF9 Q26866803-C090C56B-03A5-43F2-9BAF-53F1EEED40E6 Q27022852-EEA36962-FE4B-4995-81C7-DB98C590525F Q27024061-A46BC019-7238-4100-B386-0B4800BB0F34 Q27026323-363862D7-EFBF-45B5-A559-A5A4CF432746 Q27692653-ECF079B4-F9F7-4AC9-8BE9-C837A047A250 Q27851952-37930709-D50E-4648-BD24-77F9009CC502 Q27852360-A75ACF73-2590-4FB2-BE0E-D7F0435EF059 Q27852389-8F8B46E5-ADCF-4AFF-B090-B15AB4579AFC Q27852401-E35B707C-5AEC-4838-AAF7-3FDC46013D3A Q27852692-60EEC224-E94C-4383-AD61-AD9DF5413B8F Q27852994-373B7339-C488-4DD6-AD9D-7DC11041726D Q27853202-47D84867-223D-4ED2-BC82-509F1C17F3AC Q27853210-C28430FD-107D-4E99-9034-777381252B64 Q28079202-AEDF7337-19A8-48DB-B379-05526F4FE30B Q28282963-3CE29ECB-3763-42CF-ABC5-5A368CAAF669 Q28484649-4F0C8187-3867-494E-BDA6-F660CF93B2D9 Q28534967-640B6BA5-DC99-48F3-A33B-84E994459F62 Q28544919-D04FA2D1-33BE-40EC-8669-9B424A10521E Q28661371-B987A36A-5C5B-496F-8F38-3D936292C14D Q28817145-BACE5AB6-6226-4EB3-9A64-BA9FD0D5EEA3 Q30539324-3E60B656-4DEC-4223-91B7-DB3DA33EBE22 Q30590270-06EC8D95-A825-4E4C-B46A-86EB90D0D124 Q31114420-06876934-20D6-40ED-94C0-DC6C2B084470 Q33570013-309FA0EE-5CA9-4506-B758-8C6D479F5CC2 Q33588217-DE20FA3D-B950-4759-AB38-1F2F1C59D46D

P2860

Melanoma whole-exome sequencing identifies (V600E)B-RAF amplification-mediated acquired B-RAF inhibitor resistance

http://www.wikidata.org/entity/Q36489360

description

2012 nî lūn-bûn

@nan

2012年の論文

@ja

2012年学术文章

@wuu

2012年学术文章

@zh-cn

2012年学术文章

@zh-hans

2012年学术文章

@zh-my

2012年学术文章

@zh-sg

2012年學術文章

@yue

2012年學術文章

@zh

2012年學術文章

@zh-hant

name

Melanoma whole-exome sequencin ...... red B-RAF inhibitor resistance

@ast

Melanoma whole-exome sequencin ...... red B-RAF inhibitor resistance

@en

type

label

Melanoma whole-exome sequencin ...... red B-RAF inhibitor resistance

@ast

Melanoma whole-exome sequencin ...... red B-RAF inhibitor resistance

@en

prefLabel

Melanoma whole-exome sequencin ...... red B-RAF inhibitor resistance

@ast

Melanoma whole-exome sequencin ...... red B-RAF inhibitor resistance

@en

P1433

Q36489360-43087F24-16E8-46BB-A1FC-C6A09D022E97

P1476

Q36489360-4F69D3C8-4CC2-4B41-96C5-175AEC74860E

P2093

Q36489360-0A55FC23-DF30-48A2-AD29-8B19199E7036

Q36489360-1B40846F-9282-4B13-8E01-9DA8BAF4E7D8

Q36489360-541A0980-E675-45EA-BF1A-80D90850E9B9

Q36489360-67519947-9F73-49CC-8F68-48BBF528C6DC

Q36489360-74ED13C3-F19F-4CA9-9C23-2B16DD01A560

Q36489360-87C40BA8-3AD0-4C03-8311-E1058A55A300

Q36489360-8E08CCE8-87F8-48BF-8325-8F8A2174609D

Q36489360-90F0C4C7-FE42-4645-BBD1-B801451B4092

Q36489360-AAA4AC39-D5C2-47E9-A53B-A4AB8E3FDF77

Q36489360-AD3A99EE-FA54-4302-829F-4FA7C2D241ED

P2860

Q36489360-034B0410-A61C-4037-BF93-B2A37596F371

Q36489360-122AB7F2-2AC8-4AA8-806F-C8A2056D8B54

Q36489360-361BD45A-133E-4954-901F-42B74E86D07C

Q36489360-48C6621C-19ED-469D-9BC8-D452A43B3A21

Q36489360-57D701E7-CEB3-4A8C-86C4-A3FCB5B5A26B

Q36489360-65B1D161-933F-41B9-BF24-D4567ADECD98

Q36489360-7033318D-FD89-4AC2-A848-FFBBA66662C0

Q36489360-78EF617F-FC14-4B0E-84B8-A6BE62B243B3

Q36489360-850E0F3D-6845-45F4-9C76-32556DC537FC

Q36489360-8675A824-4CB4-4399-8B8D-23AC871CFC0B

P2888

Q36489360-89708F0A-9B6F-4470-8C98-8D743ECEB24F

P304

Q36489360-4F65EC8B-55CB-4FD0-BC83-EFC3C7C196C8

P31

Q36489360-AFE8C5BC-88CD-40E7-9EA6-881AA6DA2337

P356

Q36489360-1D2631AF-BB05-40FE-9C18-5476D96FCB86

P407

Q36489360-3BA4C62D-67C5-471F-ACFF-138FBA5AC8CB

P478

Q36489360-96F212F9-AD2B-4D66-BFEF-0AA0AE119E5F

P50

Q36489360-48B47D55-549A-4E59-9DCA-06B3A9DCEB62

Q36489360-91FB2B7D-B3F2-4C20-A2DB-1BA20452FC01

Q36489360-D92E0333-9CA6-421B-A46F-4DDBEE7EF498

Q36489360-E33E19B6-14E5-42C3-9B47-308172651953

P577

Q36489360-06DA7AF9-B19B-45E8-9B9F-DAE86E91DFF6

P5875

Q36489360-D0D081FB-FAF3-414C-8D98-24FEEBB6F6A9

P698

Q36489360-D4A1D394-A4CE-48B0-8BF0-3683785BE47C

P932

Q36489360-9D9F0606-51E3-46E4-8D82-ECF01668B91C

P356

P1433

Nature Communications

P1476

Melanoma whole-exome sequencin ...... red B-RAF inhibitor resistance

@en

P2093

Antoni Ribas

http://www.w3.org/2001/XMLSchema#string

Charles Ng

http://www.w3.org/2001/XMLSchema#string

Gatien Moriceau

http://www.w3.org/2001/XMLSchema#string

Hane Lee

http://www.w3.org/2001/XMLSchema#string

Jeffrey A Sosman

http://www.w3.org/2001/XMLSchema#string

Kimberly B Dahlman

http://www.w3.org/2001/XMLSchema#string

Mi-Kyung Lee

http://www.w3.org/2001/XMLSchema#string

Richard C Koya

http://www.w3.org/2001/XMLSchema#string

Roger S Lo

http://www.w3.org/2001/XMLSchema#string

Stanley F Nelson

http://www.w3.org/2001/XMLSchema#string

P2860

Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma

Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation

Improved survival with vemurafenib in melanoma with BRAF V600E mutation

Dissecting therapeutic resistance to RAF inhibition in melanoma by tumor genomic profiling.

Inhibition of Mutated, Activated BRAF in Metastatic Melanoma

The Genome Analysis Toolkit: A MapReduce framework for analyzing next-generation DNA sequencing data

Mutations of the BRAF gene in human cancer

A method and server for predicting damaging missense mutations

The Sequence Alignment/Map format and SAMtools

Circos: an information aesthetic for comparative genomics

P2888

P304

724

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/NCOMMS1727

http://www.w3.org/2001/XMLSchema#string

P407

P478

3

http://www.w3.org/2001/XMLSchema#string

P50

Richard A. Scolyer

Georgina V. Long

Richard F. Kefford

P577

2012-03-06T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

221682484

http://www.w3.org/2001/XMLSchema#string

P698

22395615

http://www.w3.org/2001/XMLSchema#string

P932

3530385

http://www.w3.org/2001/XMLSchema#string